Related by context. All words. (Click for frequent words.) 61 elotuzumab 61 Phase 1b clinical trials 61 LymphoStat B TM 60 HDAC Inhibitor 60 Immunotherapeutic 59 TLK# 59 PANVAC VF 59 receptor tyrosine kinase inhibitor 59 PDE4 inhibitor 59 DDP# 59 Archexin 58 Spiegelmer ® 58 Plicera 57 evaluating satraplatin 57 TRO# 57 Phase #b/#a clinical 57 Zenvia ™ 57 polycythemia vera essential thrombocythemia 57 vidofludimus 57 octreotide implant 57 HDL Selective Delipidation 57 HuMax TAC 57 PNP inhibitor 56 SinuNase ™ 56 Hedgehog antagonist 56 BN# [004] 56 Phase Ib study 56 orally administered inhibitor 56 Phase III Clinical Trials 56 REVEAL Registry 56 MAGE A3 ASCI 56 Phase IIb trials 56 Phase Ib clinical 56 EDEMA3 56 tramiprosate ALZHEMED TM 56 TRX1 56 Traficet EN 55 Symadex 55 dosing cohort 55 Troxatyl 55 SPRYCEL ® 55 Phase IIb clinical trials 55 biologic DMARD 55 EVIZON TM 55 aerosolized KL4 surfactant 55 squalamine 55 fosbretabulin 55 CYT# potent vascular disrupting 55 JAK inhibitor 55 Panzem R NCD 55 REVIVE Diabetes 55 TransVax ™ 55 forodesine 55 Annamycin 55 Phase IIB 55 IAP inhibitor 55 anti CD3 monoclonal 55 HuMax EGFr 54 TransVax tm 54 beta 1a 54 huC# DM4 54 multicenter Phase II 54 oral prodrug 54 SNS# T 54 Onconase 54 PDE# inhibitors 54 EDEMA3 trial 54 pentostatin 54 PF # [002] 54 Alzhemed TM 54 relapsed MM 54 Anturol TM 54 BLA filing 54 Pafuramidine 54 Amplimexon 54 HQK 54 phase IIb trial 54 non nucleoside inhibitor 54 pancreatic enzyme supplements 54 UPLYSO 54 confirmatory pivotal 54 Evoltra ® 54 Sphingomab TM 54 brivaracetam 54 Prestara 54 preclinical efficacy 54 Phase #/#a 54 DermaVir Patch 54 lintuzumab 54 BioNumerik 54 MGd 54 intranasal formulation 54 non CF bronchiectasis 54 atacicept 54 Silenor ® 54 BIBW 54 R#/MEM # 54 Ostabolin C TM 54 PEGylated interferon 53 histamine dihydrochloride 53 HCD# [002] 53 OvaRex ® MAb 53 TACI Ig 53 ofatumumab HuMax CD# 53 Phase IIa trials 53 MEND CABG II 53 Cimzia TM 53 PI3K/Akt pathway inhibitor 53 Phase 1a clinical 53 APEX AMI trial 53 Phase IIb III 53 recurrent herpes labialis 53 treatment naive genotype 53 CRMD# 53 varespladib 53 ONCONASE R 53 BRIM3 53 GLP toxicology studies 53 Pliaglis 53 non nucleoside HCV 53 phase IIa 53 Mesafem 53 pediatric neuroblastoma 53 PROMACTA 53 confirmatory Phase III 53 angiotensin analog 53 Bellicum 53 alvespimycin 53 phase IIb study 53 omacetaxine mepesuccinate 53 Phase Ib II 53 Allovectin 7 53 ATL# [001] 53 Tm Bioscience Cystic Fibrosis 53 IMiDs ® compound 53 generation purine nucleoside 53 relapsed acute myelogenous 53 preclinical pharmacokinetic 53 novel therapeutic antibodies 53 glucokinase activator 53 HDACi 53 Phase 2a clinical trials 53 NOX E# 53 CCR5 antagonist 53 Phase lll 53 trabectedin 53 alpha 2A 53 Cloretazine 52 Phase IIA 52 tramiprosate Alzhemed TM 52 huN# DM1 52 PRESEPT 52 Congenital Emphysema 52 Akt inhibitor 52 HCV polymerase 52 balsalazide tablet 52 oral ghrelin agonist 52 rilonacept 52 Capesaris 52 posaconazole 52 faropenem medoxomil 52 ALN HTT 52 aurora kinase 52 leukemia AML 52 treatmentof 52 Phase #b/#a 52 Tarceva TM 52 kinase inhibition 52 iSONEP 52 initiated Phase Ib 52 PMA submission 52 tyrosine kinase inhibitor TKI 52 HuLuc# 52 vaginally administered lidocaine 52 Eniluracil 52 Phase III HEAT 52 CHAMPION PCI 52 Urocidin TM 52 INS# [002] 52 DURIN TM 52 Major Depressive Disorder MDD 52 Chemophase 52 ARIKACE ™ 52 StemEx 52 AMEVIVE 52 bardoxolone 52 COSIRA trial 52 CCR1 52 keloid scarring 52 LOMUCIN TM 52 Phase #b/#a trial 52 apricitabine ATC 52 Dacogen injection 52 EGS# 52 evaluating Actimmune 52 BiDil XR 52 LB# [003] 52 genomic biomarker 52 LUMINATE 52 cannabinor 52 IMiDs R 52 Study #CL# 52 AVN# [001] 52 JAK3 52 Thorough QT Study 52 cathepsin K inhibitor 52 autosomal recessive disease 52 Aplidin 51 Neo Kidney Augment 51 E1 INT TM 51 IMC A# 51 multiple myeloma MM 51 sitaxsentan 51 phase Ib 51 PROSTVAC VF 51 GLPG# 51 BEZ# 51 ISTODAX 51 Nuvion 51 pain palliation 51 budesonide MMX ® 51 rALLy clinical trial 51 Augment Injectable 51 Diamyd ® 51 RAPTIVA 51 oral PTH 51 registrational studies 51 5 HT2C 51 Telintra 51 Stavzor TM 51 myeloproliferative diseases 51 dirucotide 51 alemtuzumab MS 51 Phase III randomized controlled 51 Androxal TM 51 ALN VSP Phase 51 pomalidomide 51 QLT# 51 paclitaxel poliglumex 51 Initiate Phase II 51 Prodarsan 51 Testosterone MDTS R 51 elacytarabine 51 MAXY alpha 51 CFTR corrector 51 Q#IR 51 zileuton CR 51 ACOMPLIA R 51 PREOS R 51 inverse agonist 51 APEX PD 51 IND submission 51 GOUT 51 IND Investigational New 51 phase IIa clinical 51 Posiphen 51 2A receptor agonist 51 demonstrated antitumor activity 51 Triapine 51 Trofex 51 ASONEP 51 PA# [002] 51 phase IIb III 51 HCV polymerase inhibitor 51 Troxatyl TM 51 stated Michelle Berrey 51 GSK# [001] 51 von Willebrand Disease 51 Fibrillex TM 51 P#Y# [002] 51 oral talactoferrin 51 Lucanix R 50 EOquin 50 Phase III psoriasis 50 CytoFabTM 50 XOMA 3AB 50 lorcaserin Phase 50 Zemplar Capsules 50 Phase Ib 50 SAR# [004] 50 ORBIT II 50 Phase 1b 50 lenalidomide dexamethasone 50 tropism testing 50 PS# DARA 50 3 registrational trial 50 POSIDUR TM 50 ARIKACE 50 NP2 Enkephalin 50 samalizumab 50 DXL# 50 ANAVEX #-# [001] 50 Hepatotoxicity 50 apoptosis inducer 50 idiopathic thrombocytopenic purpura 50 elvucitabine 50 Chronic lymphocytic leukemia 50 riociguat 50 PFO migraine 50 Pharmacokinetic studies 50 Urocortin 2 50 CIMZIA ™ 50 lintuzumab SGN 50 MEND CABG 50 PI3K inhibition 50 pharmacodynamic PD 50 Diamyd r 50 PEARL SC 50 Actimmune ® 50 www.cff.org 50 clinical pharmacology studies 50 Plenaxis TM 50 Benlysta belimumab 50 herpetic keratitis 50 Cleviprex TM clevidipine 50 TKM ApoB 50 Phase III ADT 50 AKT inhibitor 50 dacetuzumab 50 Thorough QT 50 Maxy G# 50 Phase IIIb clinical 50 ponatinib 50 eniluracil 50 Hematide ™ 50 GnRH antagonist 50 phase IIb clinical 50 budesonide foam 50 midstage clinical 50 Pagoclone 50 Urocidin 50 alagebrium 50 BCIRG 50 randomized Phase IIb 50 blinded randomized placebo controlled 50 bevasiranib 50 CG# [003] 50 Serious Adverse Events 50 NADiA ProsVue 49 EVIZON TM squalamine lactate 49 treat dysmenorrhea 49 Cethrin 49 vosaroxin 49 atypical hemolytic uremic syndrome 49 TIMP 1 49 methylnaltrexone 49 ON #.Na 49 miconazole Lauriad 49 PEG SN# 49 oxymorphone ER 49 Nasdaq MITI 49 relapsed MCL 49 IIa clinical 49 celgosivir 49 OVATURE 49 PrevOnco ™ 49 pivotal bioequivalence 49 CIMZIA TM 49 OXi# 49 defective CFTR 49 Phase IIa clinical trials 49 isavuconazole 49 SPRIX ® 49 KB# [002] 49 HIV integrase inhibitors 49 Fodosine 49 desvenlafaxine succinate 49 Phase 2a trial 49 Acute Myeloid Leukaemia AML 49 severe oral mucositis 49 registrational 49 mg/m2 dose 49 palifermin 49 MIST II 49 torezolid 49 Bicifadine 49 generation PNP inhibitor 49 maturation inhibitor 49 AIMM trial 49 JAK2 V#F 49 tobramycin inhalation solution 49 HBeAg 49 visit www.cff.org 49 SEPET TM 49 MERLIN TIMI 49 hoFH 49 P. aeruginosa infection 49 thorough QT 49 Gralise 49 ovarian cancer chronic hepatitis 49 confirmatory clinical 49 autosomal recessive genetic 49 PDE inhibitor 49 Apoptone 48 tanespimycin 48 Bevasiranib 48 VITAL Trial 48 EMPOWER ™ 48 Kahalalide F 48 Virium 48 HepeX B 48 NTx 48 fostamatinib 48 file INDs 48 im peramivir 48 Phase 1b clinical 48 phase IIb 48 membranous nephropathy 48 initiate Phase IIa 48 CML CP 48 indibulin 48 recurrent glioblastoma multiforme 48 Amikacin Inhale 48 Ceplene TM 48 Toremifene 48 forodesine hydrochloride 48 budesonide MMX Phase III 48 Pfizer maraviroc 48 mTOR inhibition 48 VersaFilm 48 visilizumab 48 dexanabinol 48 Beall Ph.D. 48 thrombin inhibiting aptamer 48 prospectively stratified 48 BrachySil TM 48 Pseudomonas lung 48 Nanobodies 48 NDA resubmission 48 ACAPODENE 48 oral rivaroxaban 48 anagrelide hydrochloride 48 HER2 overexpression 48 Raf kinase inhibitor 48 QLT Plug Delivery 48 LibiGel testosterone gel 48 Somatuline Autogel 48 PSMA ADC 48 GRALISE 48 CCR5 inhibitor 48 coadministration 48 MVax 48 midstage trials 48 pafuramidine 48 oral methylnaltrexone 48 Cf Inds Hldgs Inc 48 C1 INH deficiency 48 Wiskott Aldrich syndrome 48 LCP AtorFen 48 Chronic lymphocytic leukemia CLL 48 RSD# oral 48 haematologic 48 subcutaneous formulation 48 miglustat 48 Cerebril TM 48 romidepsin 48 Excellagen 48 ALKS 48 Feasibility Trial 48 TEC #OL 48 precursor acute lymphoblastic 48 nitrofurantoin 48 Exherin TM 48 Study NX# 48 MDS AML 48 CLIA waiver 48 DSMB recommended 48 leukemia CLL 48 RRMS patients 48 urinary N telopeptide 48 presymptomatic 48 clinicaltrials 48 phase Ib clinical 48 ERK signaling 47 Phase IIIb 47 MVA MUC1 IL2 47 LEP ETU 47 AcryMed Incorporated 47 Acute myelogenous leukemia 47 Winnipeg MB R2X 47 erythropoietic 47 cobiprostone 47 Moli# 47 thecompletion 47 elevated transaminases 47 Nasdaq PGNX today 47 OLpur TM H2H 47 Bifeprunox 47 NATRECOR ® 47 Shire BioChem Inc. 47 SILENOR ™ 47 Androgel R 47 EVIZON 47 daclizumab 47 Targretin capsules 47 PRECISE trial 47 Recap WSH 47 fibrotic disease 47 PCA3 prostate cancer 47 Phase 2a preventative 47 AERx iDMS 47 maternal serum 47 GRNVAC1 47 vaginal lidocaine 47 Recap BAL 47 Neurodex TM 47 Zavesca R 47 lorvotuzumab mertansine 47 Aurora kinase inhibitor 47 BEXXAR 47 DEEP AF 47 Hepatitis B HBV 47 imexon 47 Recap TOR 47 telaprevir VX 47 Specifid 47 randomized Phase 2b 47 biochemical relapse 47 Recap HOU 47 pharmacokinetic pharmacodynamic 47 Recap NYY 47 VP# [004] 47 dendritic cell vaccine 47 motesanib diphosphate 47 bioFILM PA TM 47 pan Bcl 2 47 CYP #D# 47 HCV antiviral 47 PhG alpha 1 47 cilengitide 47 eculizumab therapy 47 GLP1 agonist 47 e2 Collector 47 AZX# 47 SEASONALE 47 Pyridorin 47 muscarinic 47 MethyPatch 47 systemic ALCL 47 sterile lidocaine patch 47 Luramist 47 P aeruginosa 47 antibody titer 47 #I TM# 47 PRIMO CABG 47 resminostat 47 mediated inhibition 47 remission induction 47 Recap DET 47 HOLLINGER E grounded 47 TKM Ebola 46 goserelin 46 dorzolamide 46 alkylating agent 46 rindopepimut 46 ADAGIO study 46 TRIST 46 EVIZON ™ 46 oral mTOR inhibitor 46 EXJADE 46 enzyme rHuPH# 46 ritonavir boosted 46 chemokine receptor 46 phenotypic expression 46 pharmacokinetic studies 46 pafuramidine maleate 46 Tyzeka Sebivo 46 multicenter randomized placebo controlled 46 Dose escalation 46 late onset Pompe 46 NS5A 46 Somatuline R Autogel R 46 CUSTOM III 46 canakinumab 46 CLIRS 46 Zoledronic acid 46 rFVIIa 46 obatoclax 46 Recap LAA 46 ZBx 46 UVIDEM 46 PREGNANT Study 46 F#del mutation 46 Contrast Echocardiography 46 PCK# 46 chronic hyperuricaemia 46 torsemide ER 46 pulmonary P. aeruginosa 46 ANCHOR trial 46 Phase 2b kidney transplant 46 homotaurine 46 outlicensing 46 Deadlinepix 46 dose cohort 46 FOLFOX chemotherapy 46 Langerhans cell histiocytosis 46 PEP# [003] 46 ALB # 46 herpes zoster shingles 46 PCA3 assay 46 Triapine R 46 Fentanyl TAIFUN R 46 aurora kinase inhibitor 46 Mycophenolate mofetil 46 allergic airway inflammation 46 visceral metastases 46 fluorodeoxyglucose positron emission tomography 46 alpha 2A adrenoceptor 46 Phase III TRIST 46 Actilon 46 Helicobacter pylori eradication 46 BBI# 46 CBLC# 46 F#del 46 prostate cancer CaP 46 subcutaneous methylnaltrexone 46 Digital Retinal Camera 46 macitentan 46 PD2i CA 46 oncogenesis 46 mITT population 45 Phase Ia 45 Neimann Pick 45 vernakalant hydrochloride 45 alpha antagonist 45 Solazed 45 Gradoville grounded 45 APEX AMI 45 adipogenic 45 intravenous dosing 45 genotype 1a 45 Geographic Atrophy 45 Gleeson P. Eng 45 5 HT3 receptor 45 CALGB # [002] 45 chemosensitivity 45 unblinding 45 Acute Leukemia 45 rhIGF-I/rhIGFBP-3 45 Raf MEK ERK 45 pulmonary exacerbations 45 Bionutrics 45 initiate Phase IIb 45 prospectively defined 45 visit http:/www.clinicaltrials.gov/ 45 NEGRON K. grounded 45 Insulin PH# 45 specified primary endpoint 45 Clinicaltrials.gov 45 IIb clinical trial 45 4SC commented 45 nalbuphine ER 45 intradermal injection 45 Recap NYM 45 Cytolin 45 systemically administered 45 Dextofisopam 45 AdhTAP 45 ALISTA 45 randomized #:#:# 45 leukocyte adhesion 45 CHOP chemotherapy 45 ACTIVE W 45 Annexin V 45 selectively inhibits 45 IND enabling 45 dose escalation phase 45 Cytarabine Liposome Injection 45 histone deacetylase 45 steroidogenesis 45 DLTs 45 allelic variants 45 targeting PCSK9 45 NEBIDO 45 NMDA antagonist 45 DNA hypermethylation 45 inherited neurodegenerative 45 BNC# 45 ascending dose 45 bone metastasis 45 rotary VAD 45 entity NCE 45 quinoline 45 Myelodysplastic syndrome 45 Stimuvax R 45 Phase IIa proof 45 Megace 44 transaminase 44 Preclinical studies suggest 44 advanced carcinoid 44 EmbraceAC 44 NS3 protease 44 experimental allergic encephalomyelitis 44 patient derived xenografts 44 GED aPC 44 CFTR proteins 44 edifoligide 44 TRPV1 agonist 44 pulmonary Pseudomonas aeruginosa 44 intradermal injections 44 pyrimidine nucleoside analog 44 pharmacokinetic characteristics 44 mg/m2 cohort 44 MANUFACTURERS AND TRADERS 44 initiate multicenter 44 ABSSSI 44 Medulloblastoma 44 Phase 2b randomized 44 BN# [002] 44 ancrod 44 refractory chronic myeloid 44 allogeneic stem cell 44 MADIT 44 iii GTx 44 Intraject 44 cMET inhibitor 44 Stavzor ™ 44 pretransplant 44 Urokinase 44 Cintredekin besudotox 44 Woitas grounded 44 GG genotype 44 Recap TEX 44 virological response 44 AZX# Phase 44 release cysteamine bitartrate 44 cortical stimulation 44 piperacillin tazobactam 44 Virulizin R 44 initiate Phase 2b 44 Prothrombin 44 CRGN 44 neuronal dysfunction 44 G#D mutation 44 NIELSEN grounded 44 initiate Phase Ib 44 darinaparsin 44 Excellagen TM 44 ENGAGE AF TIMI 44 Niemann Pick type 44 KEY OFFSEASON SUBTRACTIONS 44 hepatic fibrosis 44 inhaled tobramycin 44 recurrent ovarian 44 Prosaptide 44 bunt SAC 44 ritonavir boosted protease inhibitor 44 Niemann Pick 44 xeroderma pigmentosum 44 RiVax ™ 44 GSK3B 44 CRACM 44 G#D 44 anthracycline unless 43 Amoxicillin PULSYS 43 IL 1ß 43 PEGPH# 43 OraTest R 43 LLY Logo http:/www.newscom.com/cgi-bin/prnh/#Annie Isler #:# 43 REMOXY ® 43 relapsed refractory 43 antituberculosis 43 Advaxis Phase 43 PRECISE Trial 43 PROCHIEVE 43 postapproval 43 Niemann Pick disease 43 Phase IIb kidney transplant 43 ß1 43 % #gt 43 hematologic toxicity 43 Btk inhibitor 43 PHILADELPHIA PHILLIES Placed 43 Maximum Tolerated Dose 43 PI3K Akt 43 dexrazoxane 43 Tetrodotoxin TTX 43 integrin receptor 43 Dystrophy 43 Recap CLE 43 lamivudine resistant 43 dose Ara 43 C conjugate vaccine 43 Rylomine TM 43 Pseudomonas aeruginosa lung 43 interferon beta 1b 43 SEASONIQUE 43 B.Abreu 43 heavily pretreated 43 C.Izturis 43 Helixate R 43 Thrombotic thromboembolic complications 43 PROJECTED LINEUP 43 Phase 1a 43 Pseudomonas infections 43 FavId 43 NS4A antagonist 43 FasL 43 development Medidata Designer 43 rFSH 43 baseman Ad.Gonzalez 43 prokinetic 43 postmenopausal estrogen 43 naltrexone hydrochloride 43 randomized multicenter Phase III 43 Cloretazine R 43 potentiation 43 GABA aminotransferase 43 nab paclitaxel 43 CELVAPAN H#N# 43 pleural mesothelioma 43 urate lowering 43 ImmuneY2 42 carcinogenicity study 42 doxorubicin docetaxel 42 humoral responses 42 Enhanze Technology 42 CF INDUSTRIES 42 IL-#/# 42 Cystic Fibrosis CF 42 WHITELEY grounded 42 lesional 42 edifoligide E2F Decoy 42 acute lymphoid leukemia 42 K. Erkert 42 HOCH grounded 42 Dose adjustments 42 Niemann Pick Disease 42 RESTORE CLI trial 42 PAUL SAINTS Signed 42 Sanfilippo Syndrome 42 Oralair R 42 solubilization 42 safflower produced 42 pegaptanib 42 IntroductionThe 42 cangrelor 42 SIMPADICO 42 thorough QTc 42 blinded randomized 42 dermaPACE ™ 42 pharmacodynamics PD 42 Grey Ruegamer G 42 solvent detergent 42 MADIT II 42 virologic failure 42 RAMIREZ grounded 42 TRA 2P 42 F.Gutierrez 42 LHP Tony Sipp 42 TDF FTC 42 opioid bowel dysfunction 42 vivo toxicology 42 punctal plug 42 pulmonary fibrosis PF 42 seasonal influenza VLP vaccine 42 ASCT 42 doxorubicin cyclophosphamide 42 Joshua Coppins NZL Aprilia 42 baseman D.Lee 42 Phase 2b MATRIX 42 PRESEPT study 42 Parkin DM 42 pegIFN 42 maximal doses 42 ABILIFY Injection 42 ZINANTI 42 clevudine 42 baseman Ad.LaRoche 42 lymph node dissection 42 retaspimycin 42 DACH platinum 42 Anormed 42 Scopus Affiliation Identifier 42 empiric 41 CLUFF grounded 41 neovascularisation 41 Inflammatory Breast Cancer 41 REMURA 41 M. Cieszko 41 CCFF 41 CPatterson 41 subcutaneous PRO 41 inecalcitol 41 JLugo 41 intranasal insulin 41 Ja.Wilson 41 Duchene Muscular Dystrophy 41 brentuximab vedotin SGN 41 OVATURE trial 41 Acute Lymphocytic Leukemia 41 tumor regressions 41 endometrial adenocarcinoma 41 treat premature ejaculation 41 pediatric pontine glioma 41 isatoribine 41 aciduria 41 transmucosal delivery system 41 CFTR gene 41 DOrtiz 41 LANDIS Rober 41 W.Valdez 41 subcutaneous dosing 41 LEAPS H#N# 41 SpacePC 41 Nasulin 41 HOLLINGER E flied 41 BEXXAR therapeutic regimen 41 RUGs IV 41 complete cytogenetic response 41 BROMDAY 41 GREAT STRIDES 41 1B Darin Erstad 41 B.Roberts 41 Aggrenox R 41 spinal muscular atrophy SMA 41 Joel Roelants BEL KTM 41 TEUFEL S. 41 2A agonist 41 recombinant follicle stimulating 41 preadmission 41 WALTON grounded 41 WASHINGTON NATIONALS Placed 41 X Excite 41 dermatology biopharmaceutical company 41 intranasal ketamine 41 B.Molina 41 Amoxicillin PULSYS Phase III 41 potent activator 41 NAKAYAMA grounded 41 downregulation 41 Phase 2a proof 40 Sebastien Pourcel FRA Kawasaki 40 cystic fibrosis CF 40 K#N 40 Pgp 40 WIENS 40 Ashley Cuticchia 40 TSX VENTURE RPX 40 A.Rodriguez 40 TORGERSON 40 Dr. Zelenetz 40 Acorda Therapeutics ACOR 40 ENRICH trial 40 I.Suzuki 40 Acute Myelogenous Leukemia AML 40 ACTILON 40 MOrdonez 40 vesicular monoamine transporter VMAT2 40 baseman G.Sanchez 40 postexposure 40 Acute Lymphoblastic Leukaemia 40 Phase III pivotal 40 STRICKLAND J 40 AQUAVAN R 40 cervicovaginal 40 Eitan Kerem 40 degenerative lumbar 40 BALTIMORE ORIOLES Placed 40 randomized blinded 40 LINDLEY N. 40 Davide Guarneri ITA Yamaha 40 GONZALES grounded 40 OCabrera 40 Steven Frossard FRA Kawasaki 40 Dood J 40 Christophe Charlier FRA Yamaha 40 Jo.McDonald 40 ARamirez 40 A.Beltre 40 OF Luis Terrero 40 Committee IDMC 40 pregnancy lactation 40 virologic response EVR 40 PIHC 40 opioid dependent 40 V.Martinez 40 Rui Goncalves POR KTM 40 M.Tejada 40 J.Fox 40 C.Jackson 40 BETAS 40 NKTR 40 CF 40 Gautier Paulin FRA Yamaha 40 eukaryotic translation 40 shortstop H.Ramirez 40 telomerase inhibition 40 daily subcutaneous injections 40 Clay B. Siegall 40 TURBT 40 Activated 3B 40 CFH gene 39 parthenolide 39 HaRamirez 39 Menerba 39 mercaptopurine 39 eIF4E 39 cervical ripening